These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The menopausal transition: how does route of delivery affect the risk/benefit ratio of hormone therapy? Shulman LP J Fam Pract; 2004 Jul; Suppl():S13-7. PubMed ID: 15251108 [No Abstract] [Full Text] [Related]
4. Health risks after cessation of postmenopausal hormone therapy. Pines A; Sturdee D; Birkhäuser M; Climacteric; 2008 Jun; 11(3):179-80. PubMed ID: 18568782 [No Abstract] [Full Text] [Related]
5. The Women's Health Initiative trial and related studies: 10 years later: a clinician's view. Gurney EP; Nachtigall MJ; Nachtigall LE; Naftolin F J Steroid Biochem Mol Biol; 2014 Jul; 142():4-11. PubMed ID: 24172877 [TBL] [Abstract][Full Text] [Related]
6. A personal initiative for women's health: to challenge the Women's Health Initiative. Genazzani AR; Gambacciani M Gynecol Endocrinol; 2002 Aug; 16(4):255-7. PubMed ID: 12396552 [No Abstract] [Full Text] [Related]
8. Clinical appraisal of the Women's Health Initiative. Speroff L J Obstet Gynaecol Res; 2005 Apr; 31(2):80-93. PubMed ID: 15771632 [No Abstract] [Full Text] [Related]
9. Hormone replacement therapy: need for reappraisal. Nath J Natl Med J India; 2002; 15(6):346-8. PubMed ID: 12540069 [No Abstract] [Full Text] [Related]
10. [Estrogens in menopause – time to change the guidelines?]. Eriksen EF; Moen MH; Iversen OE Tidsskr Nor Laegeforen; 2018 Mar; 138(6):. PubMed ID: 29557135 [No Abstract] [Full Text] [Related]
11. Where are we with postmenopausal hormone therapy in 2005? Lam PM; Chung TK; Haines C Gynecol Endocrinol; 2005 Nov; 21(5):248-56. PubMed ID: 16373243 [TBL] [Abstract][Full Text] [Related]
12. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results. Kuhl H; Stevenson J Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155 [TBL] [Abstract][Full Text] [Related]
14. Perspectives on the Women's Health Initiative trial of hormone replacement therapy. Grimes DA; Lobo RA Obstet Gynecol; 2002 Dec; 100(6):1344-53. PubMed ID: 12468183 [TBL] [Abstract][Full Text] [Related]
15. Recent epidemiological evidence relevant to the clinical management of the menopause. Shapiro S Climacteric; 2007 Oct; 10 Suppl 2():2-15. PubMed ID: 17882666 [TBL] [Abstract][Full Text] [Related]
16. Biomarkers and the risk of stroke in the Women's Health Initiative. Prentice RL Womens Health (Lond); 2011 May; 7(3):269-73. PubMed ID: 21612347 [No Abstract] [Full Text] [Related]
17. Postmenopausal hormone therapy before and after the women's health initiative study: what consequences? Mikkola TS; Clarkson TB; Notelovitz M Ann Med; 2004; 36(6):402-13. PubMed ID: 15513292 [TBL] [Abstract][Full Text] [Related]
18. Lessons learned from the WHI: HRT requires a cautious and individualized approach. Aubuchon M; Santoro N Geriatrics; 2004 Nov; 59(11):22-6. PubMed ID: 15615157 [TBL] [Abstract][Full Text] [Related]
19. The relevance of the Women's Health Initiative results on combined hormone replacement therapy in clinical practice. Lemay A J Obstet Gynaecol Can; 2002 Sep; 24(9):711-5. PubMed ID: 12360366 [TBL] [Abstract][Full Text] [Related]
20. Data analysis methods and the reliability of analytic epidemiologic research. Prentice RL Epidemiology; 2008 Nov; 19(6):785-8; discussion 789-93. PubMed ID: 18813015 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]